Mesoblast says FDA feedback supports using 12‑month pain reduction data from Phase 3 trial to underpin a BLA for rexlemestrocel‑L in chronic low back pain, with opioid reduction outcomes potentially included in product labeling.
Mesoblast says FDA feedback supports using 12‑month pain reduction data from Phase 3 trial to underpin a BLA for rexlemestrocel‑L in chronic low back pain, with opioid reduction outcomes potentially included in product labeling.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.